Trade Mark Journal No.2025/002 10 January 2025
WO0000001830728 (5)
Office of origin: United States of America
Date of International Registration:20 November 2024
Date of designation in the UK:
20 November 2024

International priority date claimed: 23 May 2024
(United States of America)
(98565008)
- Class 5
- Pharmaceutical preparations and substances for the treatment of neurological, neuropsychiatric, neurodegenerative, viral, metabolic, obesity, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, dermatological, and immune system related diseases and disorders.
Biohaven Therapeutics Ltd.
Representative: Monica Riva Talley Sterne, Kessler, Goldstein & Fox P.L.L.C., 1101 K Street N.W., 10th Floor, Washington DC 20005, UNITED STATES OF AMERICA